Navigation Links
Dendreon Announces Data on PROVENGE Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer
Date:4/19/2009

to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit www.dendreon.com.

Except for historical information contained herein, this news release contains forward-looking statements that are subject to risks and uncertainties surrounding the efficacy of PROVENGE to treat men suffering from prostate cancer, risks and uncertainties surrounding the presentation of data to the FDA and approval of product applications by the FDA and risks and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such differences include risks related to our limited operating history, risks associated with completing our clinical trials, the risk that the safety and/or efficacy results of existing clinical trials or from additional clinical trials for PROVENGE will not support approval for a biologics license, the risk that the FDA may interpret data differently than we do or require more data or a more rigorous analysis of data than expected, the risk that the FDA will not approve a product for which a biologics license has been applied, the risk that the results of a clinical trial for PROVENGE or other product may not be indicative of results obtained in a later clinical trial, risks that we may lack the financial resources and access to capital to fund required clinical trials or commercialization of PROVENGE, our dependence on the efforts of third parties, and our dependence on intellectual property. Further information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's public disclosure filings with the U.S. Securiti
'/>"/>

SOURCE Dendreon Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Reports Fourth Quarter and 2008 Year End Financial Results
2. Dendreon Announces Webcast Presentation at Eleventh Annual BIO CEO & Investor Conference
3. Dendreon Announces Webcast Presentation at 27th Annual J.P. Morgan Healthcare Conference
4. Dendreon Reports Third Quarter 2008 Financial Results
5. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
6. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
7. Dendreon Announces Webcast Presentation at UBS Global Life Sciences Conference
8. Dendreon Announces Webcast Presentation at Newsmakers in the Biotech Industry Conference
9. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
10. Dendreon Reports First Quarter 2008 Financial Results
11. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... -- On behalf of biotech client GenScript USA, ... & Spitzer, P.A. (Wilentz) secured a significant jury verdict ... excess of $10 million. The jury determined that Genewiz ... it improperly hired one or more of GenScript,s employees.  ... notwithstanding the verdict, a new trial, and remittitur. ...
(Date:2/26/2015)... , Feb. 26, 2015 Protiviti ( www.protiviti.com ... version of the Governance Portal , designed to ... and compliance (GRC) tasks across multiple business units and ... to help customers better align their controls with the ... Commission ) requirements. In response to client feedback, Protiviti ...
(Date:2/26/2015)... -- The healthcare landscape is rapidly and radically changing. To ... host its 20 th Anniversary Medical Technologies 2015: ... 10, at the Hilton San Diego Resort and Spa in ... event is a platform for global medical devices, diagnostics, life ... how to succeed in an uncertain future. Participants ...
(Date:2/26/2015)... 2015 RURO, Inc., a leading LIMS, ... 6.2 – the latest update to the bestselling commercial-off-the-shelf ... of a quick and easy method to gain better ... version, RURO engineering has enhanced the system’s support for ... amounts of sample records. , "FreezerPro has become ...
Breaking Biology Technology:Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 2Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 3Embrace the Future of Medical Technologies with Frost & Sullivan 2Embrace the Future of Medical Technologies with Frost & Sullivan 3RURO Releases FreezerPro® version 6.2 2
... Science ... ... -- DuPont was named the 2009 recipient of the Corporate Innovation Award by the ... that has made a substantial difference in the marketplace and global community., , , ...
... experiment by college students that will study how microbes grow ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20081007/38461LOGO ) , ... developed the experiment that will fly as part of the ... p.m. EST on Nov. 16 from NASA,s Kennedy Space Center ...
... 12 Hollis-Eden Pharmaceuticals, Inc. (Nasdaq: HEPH ), ... I/II open-label dose-ranging trial with Apoptone® (HE3235) for hormone-resistant ... on November 16 at the American Association for Cancer ... Boston. Apoptone, a novel steroid that is an ...
Cached Biology Technology:DuPont Receives Corporate Innovation Award 2DuPont Receives Corporate Innovation Award 3DuPont Receives Corporate Innovation Award 4Students Send Microbe Experiment on Space Shuttle Atlantis 2Students Send Microbe Experiment on Space Shuttle Atlantis 3Hollis-Eden to Present Interim Data From Its Phase I/II Clinical Studies of Apoptone(R) (HE3235) at Molecular Targets and Cancer Therapeutics Conference 2Hollis-Eden to Present Interim Data From Its Phase I/II Clinical Studies of Apoptone(R) (HE3235) at Molecular Targets and Cancer Therapeutics Conference 3Hollis-Eden to Present Interim Data From Its Phase I/II Clinical Studies of Apoptone(R) (HE3235) at Molecular Targets and Cancer Therapeutics Conference 4Hollis-Eden to Present Interim Data From Its Phase I/II Clinical Studies of Apoptone(R) (HE3235) at Molecular Targets and Cancer Therapeutics Conference 5
(Date:2/11/2015)... , February 11, 2015 ... report "Access Control Market by Product (Cards and Readers, ... Military and Defense, Government, Industrial, Healthcare, Education) and By ... by MarketsandMarkets, the Access Control Market is ... growing at a CAGR of 10.6% between ...
(Date:2/9/2015)... , Feb. 9, 2015  Lintec of America recently ... for carbon nanotube (CNT) macrostructures, including sheets, yarns and ... (UTD). Leveraging the vast industrial resources of ... Japan , Lintec of America is forming the ... TX , focusing on scaling up the manufacturing ...
(Date:2/5/2015)... , Feb. 5, 2015  Marken is starting ... company and has launched a new marketing campaign to ... Organization (CLO).  The new campaign focuses on First ... protocol and shipments. The first headline in ... aligns Marken,s priorities with its client,s priorities. Marken recognizes ...
Breaking Biology News(10 mins):Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marken Launches New Patient-Centric Campaign 2
... immune system's pro-inflammatory response to bacterial invasion is ... called inducible nitric oxide synthase. In a study ... report that the predominantly anti-inflammatory enzyme, endothelial nitric ... production in response to infection. This discovery may ...
... Until now it has been impossible to accurately measure ... in real time and at the level of a ... Plant Biology and Stanford University are the first to ... molecular sensors to view changes in brain chemical levels. ...
... (MGH) has identified 80 new genes essential to the ... tool for inactivating genes in plants or animals. They ... that participate in the gene-silencing mechanism, which someday may ... in the journal Science and is receiving early online ...
Cached Biology News:Researchers report new pro-inflammatory role for anti-inflammatory enzyme 2Revolutionary nanotechnology illuminates brain cells at work 2Revolutionary nanotechnology illuminates brain cells at work 3Scientists identify genetic pathways essential to RNA interference 2Scientists identify genetic pathways essential to RNA interference 3
... to the maintenance of appropriate levels ... important and diverse as those involved ... stress response, antigen presentation, modulation of ... cell cycle regulation, transcription, and signalling ...
... This protein identification Service includes 1. ... protein spots 3. High-sensitive tryptic in-gel ... of samples for MALDI-MS 5. Acquisition ... via MALDI-MS (Bruker ultraflex TOF/TOF) 6. ...
... The Vibratome Company has joined forces ... introduce the Vibratome 411301 Tissue Chopper. This ... prepare sections of tissue for metabolic experiments ... and irregular specimens available at biopsy or ...
... The ProteinChip Antibody Capture ... development and optimization steps ... antibody-antigen interactions. This kit ... differentiation of multiple antigens ...
Biology Products: